Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Ewing Sarcoma-Pipeline Review H1 2017




(Medical-NewsWire.com, June 17, 2017 ) Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights


Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 8, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

For more information about this report at http://www.reportsweb.com/ewing-sarcoma-pipeline-review-h1-2017

Report Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834367/sample

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Key Company profiles

Amgen Inc
Astellas Pharma Inc
Bristol-Myers Squibb Company
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
CytRx Corp
EntreChem SL
Gradalis Inc
Incyte Corp
Leadiant Biosciences Inc
MacroGenics Inc
Merck & Co Inc
Merrimack Pharmaceuticals Inc
NanoSmart Pharmaceuticals Inc
NantKwest Inc
Novartis AG
Oncomatryx Biopharma SL
Oncternal Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Recombio SL
Shionogi & Co Ltd
Tarveda Therapeutics Inc
Tesaro Inc


Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834367/discount


List of Tables


Number of Products under Development for Ewing Sarcoma, H1 2017 11
Number of Products under Development by Companies, H1 2017 13
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 14
Number of Products under Development by Universities/Institutes, H1 2017 15
Products under Development by Companies, H1 2017 16
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 17
Products under Development by Universities/Institutes, H1 2017 18
Number of Products by Stage and Target, H1 2017 20
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 21
Number of Products by Stage and Mechanism of Action, H1 2017 23
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 24
Number of Products by Stage and Route of Administration, H1 2017 26
Number of Products by Stage and Molecule Type, H1 2017 28
Ewing Sarcoma - Pipeline by Amgen Inc, H1 2017 29
Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H1 2017 29
Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 30
Ewing Sarcoma - Pipeline by Cebiotex SL, H1 2017 30
Ewing Sarcoma - Pipeline by Celgene Corp, H1 2017 31
Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017 32
Ewing Sarcoma - Pipeline by CytRx Corp, H1 2017 32
Ewing Sarcoma - Pipeline by EntreChem SL, H1 2017 33
Ewing Sarcoma - Pipeline by Gradalis Inc, H1 2017 33
Ewing Sarcoma - Pipeline by Incyte Corp, H1 2017 34
Ewing Sarcoma - Pipeline by Leadiant Biosciences Inc, H1 2017 35
Ewing Sarcoma - Pipeline by MacroGenics Inc, H1 2017 35
Ewing Sarcoma - Pipeline by Merck & Co Inc, H1 2017 36
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017 36
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017 37
Ewing Sarcoma - Pipeline by NantKwest Inc, H1 2017 37
Ewing Sarcoma - Pipeline by Novartis AG, H1 2017 38
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H1 2017 38
Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 39
Ewing Sarcoma - Pipeline by Pfizer Inc, H1 2017 39
Ewing Sarcoma - Pipeline by Pharma Mar SA, H1 2017 40
Ewing Sarcoma - Pipeline by Recombio SL, H1 2017 41
Ewing Sarcoma - Pipeline by Shionogi & Co Ltd, H1 2017 41
Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H1 2017 42
Ewing Sarcoma - Pipeline by Tesaro Inc, H1 2017 42
Ewing Sarcoma - Dormant Projects, H1 2017 244
Ewing Sarcoma - Discontinued Products, H1 2017 245


Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834367/buy/2000


ReportsWeb.com

Priya Sisodia

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC